repatha evolocumab prefilled pen 1ml 140mg per pen 2pens per carton

Description

Indication & Scope

Repatha® is a prescription PCSK9 inhibitor indicated, in combination with diet and other lipid-lowering therapies, to reduce LDL cholesterol in adults with primary hypercholesterolemia or mixed dyslipidemia, including patients who are statin-intolerant or inadequately controlled with statins. It is also indicated to reduce the risk of myocardial infarction, stroke, and coronary revascularization in adults with established atherosclerotic cardiovascular disease (ASCVD), and for adults and adolescents aged 12 years and older with homozygous familial hypercholesterolemia (HoFH).

Mechanism: Evolocumab is a fully human monoclonal antibody that binds PCSK9, preventing PCSK9-mediated degradation of LDL receptors and increasing hepatic clearance of LDL cholesterol.
Drug class: PCSK9 inhibitor (human monoclonal antibody).
Clinical use: Treatment of hypercholesterolemia, mixed dyslipidemia, ASCVD risk reduction, and homozygous familial hypercholesterolemia.

Specification

Generic Name	Evolocumab Injection
Brand Name	Repatha®
Ingredient	Evolocumab
Dosage Form	Prefilled Pen
Package	1 ml: 140 mg/pen, 2 pens/carton
Conditions Treated	Primary hypercholesterolemia, mixed dyslipidemia, atherosclerotic cardiovascular disease, homozygous familial hypercholesterolemia
Taboos	Hypersensitivity to evolocumab or any component of the product
Place of origin	USA
Prescription type	Prescription Drug (Rx)
Storage Conditions	Store refrigerated at 2–8°C, protect from light. Do not freeze or shake. May be kept at room temperature (≤25°C) for up to 30 days.
Manufacturer	Amgen Manufacturing Limited LLC
Registration Authority	National Medical Products Administration (NMPA), China
Approval Number	SJ20180021
Approval Date	December 28, 2022
Shelf Life	24 months

How to use ?

Recommended Dose: For hypercholesterolemia, the usual starting dose is 10–20 mg once daily in the evening. Patients requiring greater LDL-C reduction may start at 20–40 mg daily. The maximum recommended dose is 40 mg once daily.

Time: Allow the prefilled pen to reach room temperature for about 30 minutes before injection.

Instructions for use: Inject subcutaneously into the abdomen, thigh, or upper arm. Rotate injection sites and continue lipid-lowering diet and other prescribed therapies.

Interaction: No clinically significant drug interactions have been identified. Repatha® may be used with statins, ezetimibe, fibrates, and other cardiovascular medications.

Side effects: Common adverse reactions include nasopharyngitis, upper respiratory tract infection, injection-site reactions, influenza, back pain, arthralgia, and headache. Serious hypersensitivity reactions may occur rarely.

Important Notice

This product should be administered only by qualified healthcare professionals in accordance with the approved prescribing information and local clinical guidelines. Dosage and administration may vary depending on patient condition, indication, and regional regulatory requirements.

Packaging & Shipping

Packaging

Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.

Shipping Methods

Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.

Export Support